Sarah Collins

UnitedHealth Group is a leading managed healthcare firm in the United States.

On September 14, Boston Scientific (BSX) was trading at a forward price-to-earnings ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x.

The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.

Boston Scientific (BSX) announced the acquisition of Veniti for $108.0 million. BSX already owns a 25% stake in Veniti.

Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.

Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 1Q17, ~$0.46 billion came from its Diabetes segment, representing ~6% of the company total.

In its Structural Heart business, Abbott Laboratories reported 1Q18 sales of $0.29 billion, registering YoY organic sales growth of 7.5%.

Johnson & Johnson (JNJ) reported sales of $3.4 billion in its consumer business in the first quarter, with 7% of it from its women’s health business.

Medtronic’s Diabetes Group performance in fiscal Q4 2018 was driven by a 25% growth for its MiniMed 670G hybrid closed-loop insulin pump.

On April 5, 2018, Roche’s (RHHBY) MS (multiple sclerosis) drug Ocrevus was denied recommendation by NICE.

Amid the increasing presence of digital technology, Johnson & Johnson (JNJ) has recognized the need to expand its channel presence.

Since early August 2016, there have been rumors of a likely buyout of Biogen (BIIB) by one of the many interested suitors in the biotechnology industry.

Halcyon The Halcyon system, Varian Medical Systems’ (VAR) recently launched cancer treatment device, aims to simplify and enhance IMRT (image-guided volumetric intensity modulated radiotherapy). The device has received clearance by the FDA (US Food and Drug Administration). By next year, Varian expects to receive regulatory approvals for the device in China and Japan. For more information […]

On June 27, 2017, Thermo Fisher Scientific announced the launch of its Oncomine Dx Target Test.

In its fiscal first quarter, Johnson & Johnson (JNJ) registered sales of $1.1 billion for its OTC (over-the-counter) business.

Stryker (SYK) registered strong 3Q16 earnings on October 27, 2016. The company’s reported earnings exceeded analysts’ estimates.

Today, Teva Pharmaceutical Industries (TEVA) announced that its Granix (tbo-filgrastim) injection has received FDA approval for a new presentation and indication.

Align Technology was trading at its 52-week high of $398.88 on September 25. The stock reported its 52-week low of $180.31 on September 28, 2017.

WTX101 has a unique action mechanism. The drug has the potential to become the standard of care for Wilson disease patients.

On September 21, 2016, the FDA approved Jannsen Pharmaceuticals’ Invokamet XR for the treatment of adults suffering from Type 2 diabetes.

Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.

The Trump administration proposed production cuts in some of the most abused opioid compounds by 10% next year.

Year-to-date, ABT stock has risen 12.8%. Over the last month, the stock has returned ~4.0%.

On July 4, Johnson & Johnson’s (JNJ) pharmaceuticals division, Janssen, received Health Canada’s approval for its drug Erleada.

Medtronic expects its MITG segment to have an organic growth rate of 4% in fiscal 2019.

Although changing consumer market dynamics pose challenges for Johnson & Johnson (JNJ), it’s confident it will be able to adapt.

According to Leerink analyst Amy Fadia, Fulphila is expected to generate sales of $73.0 million in 2018. Fadia expects Fulphila’s sales to reach $260.0 million in 2019.

Boston Scientific (BSX) was trading at $27.9 on June 29, 2017.

Johnson & Johnson’s key innovation strategies include creating value through strategic customer partnerships and solutions.

Varian Medical Systems (VAR) will announce its 1Q18 earnings results on January 24, 2018. It wants to establish itself as the leading cancer management company in the world.

On September 20, Mylan and its partner, Fujifilm Kyowa Kirin Biologics, received the marketing authorization from the European Commission for Hulio.

Alere’s integration synergies in 1Q18 were delivered through strong performance of the company’s Rapid Diagnostics business.

UnitedHealth Group is, by revenue, the largest healthcare company in the world.

China contributes significantly to Abbott’s Established Pharmaceuticals division, which registered sales of ~$1.1 billion, representing year-over-year growth of ~10.0%.

Teva Pharmaceutical Industries has the largest generics product pipeline in the industry. It has 325 applications that are awaiting FDA approval.

Sanofi and Regeneron are conducting clinical studies for the treatment of a range of type 2 inflammation conditions with Dupixent.

Johnson & Johnson (JNJ) is focused on growth driven by innovation, which has led to new categories or enhanced standards of care.

On July 27, 2017, Baxter International (BAX) completed the acquisition of Claris Injectables, which is expected to help expand and strengthen Baxter’s core capabilities.

In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.

In 1Q18, Teva Pharmaceutical (TEVA) reported sales of $30 million from the sales of its Austedo drug.

Teva’s Austedo, approved by the FDA in April 2017, is one of the company’s major growth drivers.

Today, Biogen (BIIB) and partner Eisai presented highly anticipated detailed study data for their investigational Alzheimer’s drug BAN2401.

Three months after announcing a $5.8 billion deal in which Abbott Laboratories (ABT) would buy Alere (ALR), Alere rejected Abbott’s $50 million offer to end the deal. On December 7, Abbott sued Alere to terminate the deal.

C.R. Bard (BCR) has grown significantly outside the United States in recent years, driven by its international channel expansion strategy.

Yesterday, Teva Pharmaceutical Industries (TEVA) announced the exclusive FTF (first-to-file) launch of the generic Cialis1 tablets in the US.

Abbott Laboratories posted a strong earnings results on January 24, surpassing Wall Street estimates and posting earnings at the high end of its guidance.

Cost transformation for growth (or CTG) is Stryker’s program that focuses on driving leveraged growth by structural cost optimization.

On October 1, ABT announced that it had received a CE mark in Europe for its next-generation continuous glucose monitoring system, the Freestyle Libre 2.

On September 13, Sanofi announced a change in two of its GBUs to enable focused operations across emerging markets and mature markets.

On September 15, Sanofi and Regeneron announced Phase 3 data results for Dupixent for the treatment of moderate-to-severe atopic dermatitis.